EUVIMEDEUVIMED entdecken
Fallbericht

Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer

Marlena Orlikowska

OncoReview · 2020

DOI: 10.24292/01.or.120250320 ↗

Kurz gefasst

Fallbericht in der Zeitschrift OncoReview, 2020. Verfasst von Marlena Orlikowska. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer is the second leading cause of cancer-related death worldwide. Trifluridine/tipiracil is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for, currently available therapies. In this report, we present a case of chemotherapy using trifluridine/tipiracil confirming the effectiveness of this drug primarily in the term of prolongation of progression free survival

Zitieren

APA

Orlikowska, M. (2020). Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer. OncoReview. https://doi.org/10.24292/01.or.120250320

Vancouver

Orlikowska M. Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer. OncoReview. 2020. doi:10.24292/01.or.120250320

BibTeX
@article{Orlikowska2020,
  author = {Orlikowska, Marlena},
  title = {Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer},
  journal = {OncoReview},
  year = {2020},
  doi = {10.24292/01.or.120250320}
}
Kostenlos starten →